EAHP represents over 29,000 hospital pharmacists across 36 member countries. EAHP represents and develops the hospital pharmacy profession within Europe in order to ensure the continuous improvement of care and outcomes for patients in the hospital setting. This is achieved through science, research, education, practice, as well as sharing best-practice and responsibility with other healthcare professionals.
The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
The EAHP staff supports the Board in executing EAHP’s mission. The Staff assists in financial management, events organisations, policy activities and all EAHP projects. The EAHP staff works closely with EAHP’s members and ensures the effective communication all relevant stakeholders.
The first member countries were Belgium, Britain, Denmark, France, the Federal Republic of Germany and The Netherlands in 1972. EAHP has now 36 EAHP members and 2 Associate Members. EAHP is open to countries members of the Council of Europe and since 2022 to organisations representing the interests of hospital pharmacists from outside the Council of Europe (Associate Membership)
EAHP’s structure is also composed by different standing committes: EAHP Scientific Committee, EAHP Education Executive Committee and the EAHP CTF Steering Committee.
Keep up with all EAHP’s events and webinars. Contact the team at info@eahp.eu should you have any questions about upcoming events or activities.
Here you can find all upcoming events organised by EAHP and by all its members and associate members. Do not hesitate to contact the events team at events@eahp.eu should you have any questions about the organisation of these events.
Hospital pharmacists conduct a critical role in the care of patients in hospitals. Learn more about what they do here and in all the pages under Hospital Pharmacy practice and Policy.
Self-Assessment
SILCC
Closed SIGs
EAHP brings together experts from many areas of hospital pharmacy practice providing and highlighting good local sustainable practices as that can be up-scaled and shared with other countries. The EAHP Working Group on Sustainability has the aim of reducing the environmental burden of the hospital pharmacy services.
The European Association of Hospital Pharmacists (EAHP), and its 36 member country platforms are creating a Common Training Framework for the hospital pharmacy education in Europe. The goal of this project is to allow the free movement of hospital pharmacists within the European Union.
The European Association of Hospital Pharmacists (EAHP) and the European Society of Clinical Pharmacy (ESCP) have collaboratively developed the Oath to Society. The Oath to Society is all encompassing and acts as a contract for excellence in providing compassionate patient care, working as part of the healthcare team and advancing the pharmacy profession, and showcasing how clinical and hospital pharmacists work every day
A day created to highlight the importance and to celebrate the work done by hospital pharmacies. This day celebrates all hospital pharmacy teams.
Catch up with EAHP’s press releases
Find all EAHP relevant publication like the EAHP Surveys, annual reports and the history books.
The European Journal of Hospital Pharmacy (EJHP) is the only official journal of the European Association of Hospital Pharmacists (EAHP) and is committed to advancing the science, practice and profession of hospital pharmacy. As the premier communication platform for hospital pharmacists worldwide, EJHP is a major source for continuing education as well as updates on advances in the practice and standard of pharmaceutical care for patients.
When EAHP and Hospital pharmacists appear in the news.
EAHP publishes a monthly EU monitor with updates about the latest EAHP initiatives and information relevant for the hospital pharmacy profession.
Sponsor Channel
The Sponsor Channel is designed to maximise visibility and engagement, allowing sponsors to connect with the hospital pharmacy community and partners in a dynamic and interactive environment. From product demonstrations to networking sessions, the Sponsor Channel offers a range of opportunities for sponsors to showcase their offerings and generate leads in the new EAHP Website.
Patient Safety and Quality Assurance
Arantxa Andújar-Mateos, José Manuel del Moral-Sánchez, Inmaculada Sánchez-Martínez, Francisco Valiente-Borrego, María Muros-Ortega, Andrés Navarro-Ruiz
When the National Institute for Occupational Safety and Health (NIOSH) published a list that included drugs considered dangerous for general and reproductive health, we had to devise a protocol in our field so that parenteral drugs could be administered in a safe way for health personnel.
The aim of our study is to determine the integration into clinical practice of a protocol for the administration of dangerous depot drugs in the social health field after a year has elapsed since its implementation.
The Depot Dangerous Drug Administration Protocol was intended to increase the safety of healthcare personnel in their preparation and administration. The recommendations contained therein, issued by official agencies and in force at the time, were transmitted by different means of communication: – Verbal: in a physical meeting with the nursing coordination of all the residences. – Written: through the distribution of the protocol via e-mail and in folders shared with the centers. – Audiovisual: elaboration and diffusion of a video explaining the preparation of the different drugs affected. For its implementation, the points mentioned in the previous section were implemented and a reference pharmacist was made available to each residence to resolve any doubts in this regard. Within a year of its implementation, from our socio-sanitary pharmacy service and in collaboration with the 16 residences specialising in geriatrics, disability and mental illness, the degree of adaptation to the protocol was measured.
In December 2017, the aforementioned protocol was implemented in the 16 residences. Within a year, more than half of the residences, 9 of the 16, acknowledged not taking any of the precautions indicated in the protocol. Of the rest of the residences, 4 stated that they have adopted all the recommendations in each preparation and administration of dangerous drugs and the remaining 3 placed their adaptation to the protocol at between 25% and 50%.
We believe it is necessary to reinforce the information contained in the protocol every 1−2 months in person. It is also necessary to keep the protocol continuously updated to detect changes in it.
